HEB Financial Facts
Total costs and expenses: 2.83MResearch and development: 900K
See Full Income Statement
Accumulated deficit: -296.47M
Additional paid-in capital: 313.62M
See Full Balance Sheet
Hemispherx Biopharma, Inc. (HEB) Earnings
|
Expand Research on HEB
Next EPS Date | N/A | EPS Growth Rate | N/A |
---|---|---|---|
Average EPS % Beat Rate | N/A | Revenue Growth Rate | N/A |
Average % Move 1-Wk after EPS | N/A | Normal Earnings Time | After Close |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
11/14/16 | Q316 | -$0.30 | N/A | N/A | N/A | N/A | N/A | Details | |||
8/15/16 | Q216 | -$0.01 | N/A | N/A | N/A | N/A | N/A | Details | |||
5/16/16 | Q116 | -$0.01 | N/A | N/A | N/A | $40.99M | N/A | Details | |||
3/29/16 | Q415 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
8/13/15 | Q215 | -$0.04 | N/A | N/A | N/A | N/A | N/A | Details | |||
5/13/15 | Q115 | -$0.02 | N/A | N/A | N/A | N/A | N/A | Details | |||
11/8/13 | Q313 | -$0.03 | N/A | N/A | N/A | N/A | N/A | Details | |||
11/5/12 | Q312 | -$0.04 | N/A | N/A | N/A | N/A | N/A | Details |